WHO and UNICEF National Immunization Coverage Estimates Summary
Core Content
The World Health Organization (WHO) and United Nations Children's Fund (UNICEF) jointly estimate national immunization coverage levels for various vaccines across different years. These estimates are based on data from multiple sources, including administrative reports, official assessments, and surveys. However, due to the variability and sometimes unknown quality of the data, the estimates are not always fully reliable. The Grade of Confidence (GoC) is used to indicate the level of empirical support for each estimate.
Main Vaccine Coverage Estimates
| Vaccine |
Description |
Coverage Type |
| BCG |
Percentage of births who received one dose of Bacillus Calmette Guerin vaccine. |
Not provided in the table |
| DTP1 |
Percentage of surviving infants who received the 1st dose of diphtheria and tetanus toxoid with pertussis containing vaccine. |
Not provided in the table |
| DTP3 |
Percentage of surviving infants who received the 3rd dose of diphtheria and tetanus toxoid with pertussis containing vaccine. |
Provided in the table |
| Pol3 |
Percentage of surviving infants who received the 3rd dose of polio containing vaccine. |
Provided in the table |
| MCV1 |
Percentage of surviving infants who received the 1st dose of measles containing vaccine. |
Provided in the table |
| MCV2 |
Percentage of children who received the 2nd dose of measles containing vaccine. |
Provided in the table |
| RCV1 |
Percentage of surviving infants who received the 1st dose of rubella containing vaccine. |
Not provided in the table |
| HepB3 |
Percentage of surviving infants who received the 3rd dose of hepatitis B containing vaccine following the birth dose. |
Provided in the table |
| Hib3 |
Percentage of surviving infants who received the 3rd dose of Haemophilus influenzae type b containing vaccine. |
Provided in the table |
| RotaC |
Percentage of surviving infants who received the final recommended dose of rotavirus vaccine. |
Provided in the table |
| PcV3 |
Percentage of surviving infants who received the 3rd dose of pneumococcal conjugate vaccine. |
Provided in the table |
| YFV |
Percentage of surviving infants who received one dose of yellow fever vaccine. |
Not provided in the table |
Coverage Data and Grade of Confidence (GoC)
DTP3 Coverage
| Year |
Estimate |
GoC |
| 2010 |
97 |
●● |
| 2011 |
97 |
●● |
| 2012 |
97 |
●● |
| 2013 |
97 |
●● |
| 2014 |
96 |
●● |
| 2015 |
95 |
●● |
| 2016 |
95 |
●● |
| 2017 |
94 |
●● |
| 2018 |
93 |
●● |
| 2019 |
94 |
●● |
| 2020 |
94 |
●● |
| 2021 |
95 |
●● |
Pol3 Coverage
| Year |
Estimate |
GoC |
| 2010 |
97 |
●● |
| 2011 |
97 |
●● |
| 2012 |
97 |
●● |
| 2013 |
97 |
●● |
| 2014 |
96 |
●● |
| 2015 |
95 |
●● |
| 2016 |
95 |
●● |
| 2017 |
94 |
●● |
| 2018 |
93 |
●● |
| 2019 |
94 |
●● |
| 2020 |
94 |
●● |
| 2021 |
95 |
●● |
MCV1 Coverage
| Year |
Estimate |
GoC |
| 2010 |
96 |
●● |
| 2011 |
96 |
●● |
| 2012 |
96 |
●● |
| 2013 |
96 |
●● |
| 2014 |
96 |
●● |
| 2015 |
95 |
●● |
| 2016 |
94 |
●● |
| 2017 |
93 |
●● |
| 2018 |
93 |
●● |
| 2019 |
94 |
●● |
| 2020 |
94 |
●● |
| 2021 |
93 |
●● |
MCV2 Coverage
| Year |
Estimate |
GoC |
| 2010 |
96 |
●● |
| 2011 |
96 |
●● |
| 2012 |
96 |
●● |
| 2013 |
96 |
●● |
| 2014 |
96 |
●● |
| 2015 |
95 |
●● |
| 2016 |
94 |
●● |
| 2017 |
93 |
●● |
| 2018 |
93 |
●● |
| 2019 |
94 |
●● |
| 2020 |
94 |
●● |
| 2021 |
93 |
●● |
Key Information
- Data Sources: WHO and UNICEF use data from administrative reports, official assessments, and surveys to estimate immunization coverage. These data may be subject to inaccuracies or biases.
- Grade of Confidence (GoC): The GoC indicates the level of empirical support for each estimate. It is not a measure of data quality but rather the degree of support from various data sources.
- Estimate Types:
- Estimate: Based on available data, recalculated with an independent denominator, and possibly supported by surveys.
- Official: Estimated coverage reported by national authorities, reflecting their assessment.
- Administrative: Based on administrative reports from health service providers.
- Survey: Based on population-based household surveys among children aged 12-23 months or 24-35 months.
- Methodology:
- In cases where data is missing for a specific country/vaccine/year, interpolation is used to estimate coverage.
- For countries with mixed data sources showing large variation, the most likely estimate is identified.
- The GoC is described in three levels:
- ●●●: Well-supported by data, recalculated denominator, and survey.
- ●●: Supported by at least one data source and no conflicting data.
- ●: No accepted empirical data, or data from at least one source challenges the estimate.
- Uncertainty:
- No classical measures of uncertainty, such as confidence intervals, are presented.
- Subjective plausibility ranges are not estimated.
- Estimates should be used with caution and evaluated based on the objective.
Notes
- For 2021, coverage data reflects doses administered beyond the first year of life due to disruptions caused by the COVID-19 pandemic.
- IPV coverage began in 2015 as part of the Global Polio Eradication Initiative's strategy.
- HepB3 and Hib3 coverage estimates are based on the World Population Prospects and national data.
- RotaC and PcV3 are also based on national data and recalculated denominators.
- Survey data is not available for the vaccines listed in the tables.